2-[4,5-Difluoro-2-(2-Fluorobenzoylamino)-Benzoylamino]Benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5735-5743

  Strand, Mårten ^a   Islam, Koushikul ^a   Edlund, Karin ^a   Öberg, Christopher T ^a   Allard, Annika ^a   Bergström, Tomas ^b   Mei, Ya Fang ^a   Elofsson, Mikael ^a   Wadell, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (2 BENZOYLAMINO) BENZOYLAMINO]BENZOIC ACID; 2 [4,5 DIFLUORO 2 (2 FLUOROBENZOYLAMINO) BENZOYLAMINO]BENZOIC ACID; ACICLOVIR; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE DEFICIENCY; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

ACYCLOVIR; ADULT; AGED, 80 AND OVER; ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; VIRAL PLAQUE ASSAY;

EID: 84868007915     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01072-12     Document Type: Article

References (66)

1. Allard A, Albinsson B, Wadell G. 2001. Rapid typing of human adenovirusesbya general PCR combined with restriction endonuclease analysis. J. Clin. Microbiol. 39:498-505.
2. Andersson EK, et al. 2010. Small-molecule screening using a whole-cell viral replication reporter gene assay identifies 2-{[2-(benzoylamino)benzoyl] amino}-benzoic acid as a novel antiadenoviral compound. Antimi-crob. Agents Chemother. 54:3871-3877.
3. Bacon TH, Boon RJ, Schultz M, Hodges-Savola C. 2002. Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis. Antimicrob. Agents Chemother. 46:3042-3044.
4. Bacon TH, Howard BA, Spender LC, Boyd MR. 1996. Activity of penciclovir in antiviral assays against herpes simplex virus. J. Antimicrob. Chemother. 37:303-313.
5. Berardi A, et al. 2011. Neonatal herpes simplex virus. J. Matern. Fetal Neonatal Med. 1(Suppl 24):88-90.
6. Beutner KR. 1995. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. 28:281-290.
7. Blot N, et al. 2000. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant. 26:903-905.
8. Boon RJ, et al. 2000. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialie: a UK-based survey. J. Antimicrob. Chemother. 46:324-325.
9. Boyd MR, Safrin S, Kern ER. 1993. Penciclovir - a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. 4:3-11.
10. Buxbaum S, et al. 2003. Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med. Microbiol. Immunol. 192:177-181.
11. Cantin EM, Chen J, McNeill J, Willey DE, Openshaw H. 1991. Detection of herpes simplex virus DNA sequences incorneal transplant recipients by polymerase chain reaction assays. Curr. Eye Res. 10(Suppl):15-21.
12. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. 1989. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N. Engl. J. Med. 320:297-300.
13. Chen Y, et al. 2000. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31:927-935.
14. Chretien F, et al. 1996. Herpes simplex virus type 1 encephalitis in acquired immunodeficiency syndrome. Neuropathol. Appl. Neurobiol. 22: 394-404.
15. Christophers J, et al. 1998. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob. Agents Chemother. 42:868 - 872.
16. Coen DM, Schaffer PA. 1980. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. Natl. Acad. Sci. U. S. A. 77:2265-2269.
17. Corey L, Wald A. 2009. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med. 361:1376-1385.
18. Elion GB, et al. 1977. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A. 74:5716-5720.
19. Englund JA, et al. 1990. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann. Intern. Med. 112:416-422.
20. Filen F, Strand A, Allard A, Blomberg J, Herrmann B. 2004. Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions. Sex. Transm. Dis. 31:331-336.
21. Fleming DT, et al. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
22. Flomenberg P, et al. 1994. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J. Infect. Dis. 169:775-781.
23. Gaudreau A, Hill E, Balfour HH, Jr, Erice A, Boivin G. 1998. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J. Infect. Dis. 178:297-303.
24. Greenberg MS, et al. 1987. A comparative study of herpes simplex infections in renal transplant and leukemic patients. J. Infect. Dis. 156:280-287.
25. Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ. 1999. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 289:448-454.
26. Haddow LJ, et al. 2006. Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex. Transm. Infect. 82:255-259.
27. Heid CA, Stevens J, Livak KJ, Williams PM. 1996. Real time quantitative PCR. Genome Res. 6:986-994.
28. Heim A. 2011. Advances in the management of disseminated adenovirus disease in stem cell transplant recipients: impact of adenovirus load (DNAemia) testing. Expert Rev. Anti Infect. Ther. 9:943-945.
29. Hjalmarsson A, Blomqvist P, Skoldenberg B. 2007. Herpes simplex encephalitis in Sweden, 1990-2001: incidence, morbidity, and mortality. Clin. Infect. Dis. 45:875-880.
30. Khetsuriani N, Holman RC, Anderson LJ. 2002. Burden of encephalitis-associated hospitalizations in the United States, 1988-1997. Clin. Infect. Dis. 35:175-182.
31. Kimberlin DW. 2007. Management of HSV encephalitis in adults and neonates: diagnosis, prognosis and treatment. Herpes 14:11-16.
32. La Rosa AM, et al. 2001. Adenovirus infections in adult recipients of blood and marrow transplants. Clin. Infect. Dis. 32:871-876.
33. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. 1987. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N. Engl. J. Med. 316:1444-1449.
34. Langston AA, et al. 2002. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 99:1085-1088.
35. Liesegang TJ. 2001. Herpes simplex virus epidemiology and ocular importance. Cornea 20:1-13.
36. Matthews JT, Carroll RD, Stevens JT, Haffey ML. 1989. In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme. J. Virol. 63:4913-4918.
37. Meyers JD, Flournoy N, Thomas ED. 1980. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J. Infect. Dis. 142:338-346.
38. Miller WH, Miller RL. 1982. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem. Pharmacol. 31:3879-3884.
39. Moulignier A, et al. 1996. Fatal brain stem encephalitis due to herpes simplex virus type 1 in AIDS. J. Neurol. 243:491-493.
40. Nahmias AJ, Lee FK, Beckman-Nahmias S. 1990. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. Suppl. 69:19-36.
41. Naik HR, Siddique N, Chandrasekar PH. 1995. Foscarnet therapy for acyclovir-resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 21:1514-1515.
42. Oberg CT, et al. 2012. Synthesis, biological evaluation, and structure-activity relationships of 2-[2-(benzoylamino)benzoylamino]-benzoic acid analogs as inhibitors of adenovirus replication. J. Med. Chem. 55: 3170-3181.
43. Razonable RR. 2011. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 86:1009-1026.
44. Reardon JE, Spector T. 1989. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 264:7405-7411.
45. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. 1991. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 142:257-265.
46. Safrin S, et al. 1994. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 169:193-196.
47. Saijo M, et al. 2002. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV (r) virus. J. Med. Virol. 68:99-104.
48. Samra Z, Scherf E, Dan M. 2003. Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel. Sex. Transm. Dis. 30:794-796.
49. Schacker T, Zeh J, Hu HL, Hill E, Corey L. 1998. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J. Infect. Dis. 178: 1616-1622.
50. Schaeffer HJ, et al. 1978. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272:583-585.
51. Seidemann K, et al. 2004. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am. J. Transplant. 4:2102-2108.
52. Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. 1985. Adeno-virus infections in patients undergoing bone-marrow transplantation. N. Engl. J. Med. 312:529-533.
53. Siegal FP, et al. 1981. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. 305:1439-1444.
54. Singh N, et al. 1988. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J. Infect. Dis. 158:124-131.
55. Smith JS, Robinson NJ. 2002. Age-specific prevalence of infection with herpes simplex virus types2and1:aglobal review. J. Infect. Dis. 186(Suppl 1):S3-S28.
56. Sutton D, Boyd MR. 1993. Comparative activity of penciclovir and acy-clovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob. Agents Chemother. 37:642-645.
57. Tyring SK, Baker D, Snowden W. 2002. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J. Infect. Dis. 186(Suppl 1):S40-S46.
58. Umar SH, Kanth A. 1999. Disseminated cutaneous herpes simplex virus type-1 with interstitial pneumonia as a first presentation of AIDS. J. Natl. Med. Assoc. 91:471-474.
59. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpes-virus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33:1765-1773.
60. Wagstaff AJ, Bryson HM. 1994. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocom-promised patients with viral infections. Drugs 48:199-226.
61. Wagstaff AJ, Faulds D, Goa KL. 1994. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153-205.
62. Wald A, Link K. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185:45-52.
63. Wald A, et al. 2000. Reactivation of genital herpes simplex virus type 2 infectionin asymptomatic seropositive persons. N. Engl. J. Med. 342:844-850.
64. Weller S, et al. 1993. Pharmacokinetics of the acyclovir pro-drug valaci-clovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595-605.
65. Whitley RJ. 2006. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 71:141-148.
66. Whitley RJ, Roizman B. 2001. Herpes simplex virus infections. Lancet 357:1513-1518.